PepGen reposted this
We can’t wait for the beautiful scenery and special moments Camp Promise - Rockies brings each year! ⛰️ To help provide a great camp experience, we ask for your support in obtaining items from our Amazon Wish List. Support or share: https://lnkd.in/eYACR2Vf
Meet Shaoxia Yu, Principal Scientist, here at PepGen. Specializing in our bioanalytics, biomarkers, and DMPK functions, Shaoxia's notable work has contributed towards advancing various stages of our drug development efforts. To learn more about our team, visit: https://bit.ly/48UJ8Ch
Ever wondered what sets our EDO platform apart? Hear from CMO Dr. Michelle Mellion, as she dives into the innovative approach powering our pipeline of potentially disease-modifying candidates. Discover how we're redefining possibilities in the neuromuscular and neurology space by potentially enhancing the delivery of oligonucleotides.
During the IDMC-14 International Myotonic Dystrophy Consortium Meeting in April, the advocacy group Stichting MD created a video titled 'What’s Happening Now,' featuring the DM1 community discussing what matters most to them about #MyotonicDystrophy. Check out the video below to listen to the insights of Jennifer Shoskes, PharmD, Associate Director, Clinical Development and others. #MyotonicDystrophy #Awareness #Advocacy https://lnkd.in/eF2pxjbW
School may be out for summer, but #ProfessorPepGen is back with Lesson 2, “the Phases of Rare Disease clinical trials”. Check it out here! #patientadvocacy #clinicaltrials #biotech #patienteducation
We are looking forward to reporting preliminary data from the 5 mg/kg cohort of our CONNECT1 trial in DMD, expected mid-year. This will be followed with preliminary data from the higher 10 mg/kg dose cohort, further advancing our goal of transforming the treatment landscape for DMD. https://lnkd.in/ensfjvrF
We are excited to announce the expansion of our executive team with the appointments of Afsaneh Mohebbi, PhD as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA as Senior Vice President, Investor Relations and Corporate Communications. Their experience will enhance PepGen’s expertise in critical areas of the organization, and we eagerly anticipate their contributions as we prepare for numerous key clinical milestones in the second half of this year. https://lnkd.in/eXBwvhfA
Congratulations Hayley Parker, SVP of Global Regulatory Affairs, for being selected as one of Endpoints News’ LGBTQ+ Leaders in Biopharma ’24. It is an honor to have Hayley as part of our PepGen team, where she has been an integral player in promoting our inclusive work environment. Hayley is one of 15 biopharma leaders honored this year. We want to take a moment to thank each of these individuals for helping make the biotech industry more welcoming for the LGBTQ+ community. Read more here: https://lnkd.in/gSEAt4s6 Join the Endpoints team this morning at 11am ET for a virtual event to celebrate and hear insights from this year’s honorees. Register here: https://lnkd.in/eE8eBWCQ #HappyPrideMonth
Meet Sejal Batra, MS, Clinical Project Manager here at PepGen. Sejal plays a crucial role in ensuring that our CONNECT1 clinical trial for DMD is conducted effectively, on schedule while maintinaing compliance with regulations and protocols. To learn more about our team visit: https://bit.ly/48UJ8Ch
We are one week away from the PPMD’s 30th Annual Conference! PepGen is excited to attend another engaging conference hosted by Parent Project Muscular Dystrophy. For more info: https://bit.ly/4bYps1s
